Tag: NPH
Cerevasc announces first patient randomised to eShunt system treatment in STRIDE...
Cerevasc has announced that the first patient has been randomised to and treated with the eShunt system in its STRIDE clinical trial—a head-to-head comparison of...
STRIDE trial assessing eShunt treatment for normal-pressure hydrocephalus gains approval in...
Cerevasc announced recently that it has received approval from Argentina's National Administration of Drugs, Food and Medical Devices (ANMAT) to initiate the STRIDE trial—a...
Cerevasc announces positive eShunt study results in elderly NPH patients
Cerevasc has today reported initial results from its pilot US Food and Drug Administration (FDA)-approved investigational device exemption (IDE) clinical study of the eShunt...
Cerevasc announces first enrolment in STRIDE trial evaluating eShunt system for...
Cerevasc has announced the first enrolment of a patient in the STRIDE clinical trial evaluating the company’s eShunt system in patients with normal-pressure hydrocephalus...
EShunt system receives US FDA Breakthrough Device designation for hydrocephalus treatment
Cerevasc has announced it has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its eShunt system, which is intended...
Cerevasc announces US FDA-approved expansion of normal-pressure hydrocephalus study
Cerevasc has announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of...
First patient treated in clinical trial of CereVasc’s eShunt system for...
CereVasc has announced treatment of the first patient in its clinical study of the eShunt system in patients with normal-pressure hydrocephalus (NPH).
Following approval from Argentina's...
